Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.37 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6059650 | 0.92 | CA12 (0.39) | CA12CA1CA9CYP3A4CYP2C9 | |
| SCHEMBL6060301 | 0.84 | CA12 (0.35) | CA12CA1CA9PSMD10CYP24A1 | |
| SCHEMBL9172553 | 0.84 | CYP3A4 (0.37) | CA12CA1CA9CYP3A4CYP2C9 | |
| SCHEMBL6060897 | 0.83 | CA12 (0.35) | CA12CA1CA9PSMD10CYP24A1 | |
| SCHEMBL6060447 | 0.82 | CA12 (0.34) | CA12CA1CA9PSMD10CYP24A1 | |
| SCHEMBL6060506 | 0.81 | MCHR1 (0.36) | CA12CA1CA9PSMD10CYP24A1 | |
| SCHEMBL6060325 | 0.81 | MCHR1 (0.36) | CA12CA1CA9PSMD10CYP24A1 | |
| SCHEMBL13242117 | 0.78 | CA12 (0.41) | CA12CA1CA9CYP3A4CYP2C9 | |
| SCHEMBL6060394 | 0.77 | CA12 (0.35) | CA12CA1CA9CYP3A4CYP2C9 | |
| SCHEMBL6060048 | 0.76 | CA12 (0.37) | CA12CA1CA9CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071344-B1 | Vitamin D derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments | SCHERING AG (DE) | 2006-07-04 | — | — | US | disclosed |
| US-20050227951-A1 | Verification of translation | STEINMEYER ANDREAS | 2005-10-13 | — | — | US | disclosed |
| EP-1025082-B1 | NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | STEINMEYER ANDREAS (DE) | 2003-01-23 | — | — | US | disclosed |
| EP-1025082-A1 | NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999016745-A1 | NOVEL VITAMIN D DERIVATIVES WITH CYCLOPROPYL RINGS IN THE LATERAL CHAINS, A METHOD AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THE UTILIZATION THEREOF FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227951-A1 | Verification of translation | CYP2R1, CYP24A1, VDR | CA12 2219/4885CA1 3975/4885CA9 1867/4885 |
| US-20030018194-A1 | New Vitamin D derivatives with cyclopropyl rings in the side chains, process and intermediate products for their production and their use for the production of pharmaceutical agents | CYP2R1, CYP24A1, VDR | CA12 3581/4885CA1 4362/4885CA9 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.